ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Advocacy
  • Anal cancer
  • Artificial intelligence (AI)
  • Bladder cancer
  • Brain cancer
  • Breast cancer
  • Colorectal cancer
  • ComboMATCH
  • Esophagus cancer
  • Gallbladder cancer
  • Head and neck cancer
  • Health equity
  • Immunotherapy
  • In memory
  • Kidney cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Melanoma
  • Myelodysplastic syndrome
  • Myeloma
  • NCI-MATCH
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penis cancer
  • Personalized treatment
  • Policy
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Real-world data/evidence
  • Research results
  • Sarcoma
  • Screening for cancer
  • Side effects
  • Survivorship
  • Targeted therapy
  • Upper tract urothelial cancer
  • Young adults
March 26, 2024
March 26, 2024
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E5 is testing a new option for patients with advanced solid tumors that have a KRAS G12C mutation

This study is assessing the combination of two drugs—sotorasib and panitumumab—in patients with KRAS G12C-mutated solid tumors
Do you like it?
0 Read more
October 9, 2023
Research dictionary entry
October 9, 2023
Categories
  • Trial Results

Trial Results: ECOG-ACRIN research round-up – Fall 2023

Summaries of recent publications by researchers affiliated with ECOG-ACRIN
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E4 is testing a new option for patients with advanced solid tumors that progress despite taxane chemotherapy

This study is for patients with solid tumors that are progressing after treatment with taxane therapies
Do you like it?
0 Read more
March 23, 2023
March 23, 2023
Categories
  • New Trials

The ComboMATCH precision medicine initiative is getting set to evaluate several new anti-cancer drug combinations

Hospitals and cancer centers nationwide are opening ComboMATCH on a rolling basis over the next few months
Do you like it?
0 Read more

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc